KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) (“Bio Green Med” or the “Company”), a company engaged in diversified industries, today announced that it has closed the previously announced transaction (the “Exchange Transaction”) to acquire Fitters Sdn. Bhd. (“Fitters”), a Malaysia private limited company and wholly-owned subsidiary of FITTERS Diversified Berhad, a Malaysian publicly listed company (“Fitters Parent”). Following the closin ...

文章核心观点 - 生物制药公司Cyclacel与投资控股公司FITTERS达成交易协议修正案，将收购FITTERS子公司Fitters Sub全部股份，Fitters Sub将成为Cyclacel全资子公司，交易需获双方批准 [1][2][3] 交易详情 - 依据协议Fitters Sub全部普通股将换为Cyclacel普通股，Cyclacel将发行相当于交易结束日已发行和流通股份19.99%的普通股给FITTERS，该比例可能调整 [2] - 除普通股外，Cyclacel将在交易结束时支付100万美元或双方商定金额给FITTERS作为对价 [2] - 双方同意将最终日期延至2025年9月30日 [2] - 交易需获Cyclacel股东和FITTERS批准，协议已获双方及Fitters Sub董事会一致批准 [3] 公司介绍 Fitters Sdn. Bhd. - 马来西亚私营有限公司，专业从事各类防护和消防安全材料、设备及防火系统的分销、贸易和安装，以可靠和符合严格监管标准著称 [4] - 作为“一站式”防护服装专家，提供阻燃制服和Scotchlite反光材料，总部位于吉隆坡，提供灭火器、泡沫系统等多种消防安全产品，使命是为各行业提供高质量认证安全解决方案 [8] Cyclacel Pharmaceuticals, Inc. - 临床阶段生物制药公司，基于细胞周期、表观遗传学和有丝分裂生物学开发创新癌症药物，评估PLK1抑制剂plogosertib在实体瘤和血液系统恶性肿瘤患者中的疗效，战略是基于新药候选管线打造多元化生物制药业务 [6] 其他信息 - 公司将向美国证券交易委员会提交包含代理声明和招股说明书的S - 4表格注册声明，投资者等可通过SEC网站和公司网站获取相关文件 [10] - 公司及部分董事和高管可能被视为交易中征集股东代理投票的参与者，相关信息将在S - 4表格中披露 [12]

KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; "FITTERS"), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, "Waste-To-Resource" services and real estate development and construction. Pursuant to the Exc ...